Generic prescribing for epilepsy remains controversial. This study aimed to ascertain if a change occurred in the incidence of seizures or side-effects when a different pharmaceutical manufacturer's version of the same antiepileptic drug was taken (a 'switch').
INTRODUCTION
In 1987 the Drug and Therapeutics Bulletin t recommended 'that prescribers should, wherever possible, use generic names rather than brand ones.' Should antiepileptic drugs be an exception?
Following the introduction of practice drug budgets and the development of formularies in hospitals and practices, the generic prescribing of antiepileptic drugs (AEDs) has doubled in the past 5 years 2.
Doubts about the safety of generic prescribing for epilepsy arose in 1968 following reports of an outbreak of phenytoin intoxication among patients with epilepsy who had received the drug from a different source of manufacture 3.
Evidence for the safety of generic prescribing for epilepsy is not conclusive. Reports from controlled studies are conflicting 4-~2. A British Epilepsy Association survey found that 60 (46.5%) people perceived a worsening of their condition after receiving a different supply ('switch') of the same AED 13.
The Food & Drug Administration (FDA) allow a plus or minus 20% difference in bioavailability when licensing generics compared with the branded drug H and the European guidelines, although tighter, allow a similar laxity ~s. This is probably acceptable for most drugs, but there are fears for AEDs where small changes in bioavailability may result in poorer control of seizures with consequent serious implications for the person's quality of life t6.
With this conflicting evidence it is not surprising that expert recommendations vary.
In the USA, Nuwer et a117 stated 'while generic medications offer the potential for significant cost reduction, short-term economic considerations should not be allowed to jeopardize the health of persons with epilepsy. Doing so may actually increase health care costs in addition to adversely affecting quality of life.' But Young 18 We wanted to see if we could provide evidence that may enable health decision makers to reach sensible conclusions on this issue.
The aim of the study was to ascertain whether there is a change in the incidence of seizures and side-effects when 'switching' between different suppliers of the same AED.
METHODS
General practices in the Yorkshire Health Region of three or more partners were approached to ascertain whether or not they would participate in the study.
A patient questionnaire and introductory letters were designed and piloted (available from the authors). After a visit from a study team member, recruited practices sent these to people who were identified from repeat prescription systems and/or a disease register as taking carbamazepine, phenytoin or sodium valproate for epilepsy. These three drugs were chosen because they are prescribed frequently and are available as generics. A reply paid envelope, addressed to each practice was provided for each patient contacted. Practices were reimbursed for their administration costs.
Every person who recalled taking a different supply of the same AED over the last 2 years was followed up by their practice if they reported a problem with the control of their epilepsy after a 'switch'. The person's GP discussed their perceived problems and whether any other reason except the 'switch' in supplies of their AED could be identified.
After each discussion people reporting problems were allocated to the following groups:
(1) 'switch' problems 'validated'---increase in seizure frequency or side-effects with no other identifiable medical or psychological cause.
(2) 'switch' problems unproven--increase in seizure frequency or side-effects where other likely medical or psychological explanations were identified.
(3) follow-up incomplete--increase in seizure frequency or side-effects, but the person did not respond to follow-up approaches or opted for no further contact on the questionnaire.
People who had not taken a different supply of their AED in the last 2 years or did not report problems after a 'switch' where not contacted again.
Data received has been analysed on SPSS/PC+ version 4.0.
RESULTS

Participating practices
Five hundred and fifty-six practices were contacted; 155 (27.9%) replied, of which 57 (10.3%) agreed to participate. Resources allowed 40 to be recruited on a 'first come, first served' basis. Participating practices were from a variety of geographical locations and varied in size from 4100 to 20 000 patients. Their total list size was 350 168.
People being treated for epilepsy
A total of 2285 people were contacted (0.65% of the population studied) and asked to complete the questionnaire. In all, 1343 (58.8%) replied, of which 49.9% were male and 50.1% were female. Their mean age was 45.79 with a range of 1-94 (sd, 20.80). The mean age of onset for their epilepsy was 29.88 with a range of 0-90 (sd, 24.57). Mean seizure frequency was 7.31 per month with a range of 0-600 per month (sd, 35.77).
Attitude to drug therapy (n = 1288, lower figure due to missing answers on questionnaire)
It was found that 74.5% take a close interest in their medication, 7.1% never query variations in the presentation of their drugs, but changes make them anxious, 11.9% never query variations and changes do not worry them and 6.5% do not pay close attention to the presentation of their drugs and would not have noticed variations. Experiences of people reporting a 'validated' problem A 'validated' problem after a 'switch' was reported by 27 patients (10.8%). Table 3 describes the types of problem.
Types of 'switches' for 'validated' problems (n = 27)
Problems were seen when 'switching' from a branded product to a generic product (68%), generic to brand (12%) and between generics (20%).
Antiepileptic drugs (n = 1324)
Of the patients, 37.8% reported presently taking carbamazepine, 39.2% sodium valproate and 32.6% phenytoin. (Percentages total greater than 100% because of polytherapy.) The version of these drugs being presently taken is outlined in Table 1 : 73.9% were taking monotherapy; 22.1% were taking two drugs; 3.6% were taking three; 0.4% were taking four or more.
Seizure frequency and side-effects on present medication (n = 1343)
Of the overall sample, 45.3% were seizure-free with no side-effects, 12.6% were seizure free, but reported side-effects, 26.3% considered their epilepsy to be well-controlled even though they still had seizures and 15.8% viewed their epilepsy to be poorly-controlled.
People's experiences after 'switching' in the last 2 years
A total of 251 (18.7%) had experienced a 'switch'. Table 2 shows their experiences. The categories are explained in the methodology.
Characteristics of the people who reported problems and those who did not Table 4 compares the characteristics of people who reported problems, 'validated' or not, with those reporting no problems.
DISCUSSION
Recruitment was easier than expected, suggesting that general practices were concerned, interested and welcomed further guidance on this issue. However, covering the administration costs for practices could have been a possible factor affecting response rate. Although retrospective, this study has thoroughly investigated people's perceptions of the effects of a 'switch' of antiepileptic medication. It used a broadly-based general practice population, lending greater weight to this study than previously published work. The proportion of the population studied found to have epilepsy was similar to other recent studies 23. Responders were similar in sex, seizure frequency and number of drugs taken to the same studies 23.
After 'switching', 177 patients (70.5%) experienced no problems. This could support the argument for generic prescribing of AEDs. However a sizeable minority of 74 (29.5%) reported perceived problems after a 'switch'. Factors other than differences in bioavailability could have led to people reporting problems, for example stress, worry, confusion due to changing pill size and colour, attribution bias and poor dispensing. But in 27 (10.8%), the person's GP shared their belief that the 'switch' was the principal cause.
People who reported 'validated' problems could not be differentiated significantly from those reporting no problems in terms of seizure frequency or number of medications taken. The only significant difference was in attitude towards drug therapy with those who reported 'validated' problems taking a closer interest. This suggests the disease pattern for those reporting 'validated' problems is no different from those reporting no problems, but that people who take a close interest in their medication are more likely to report problems.
All three most-commonly prescribed AEDs were associated with 'validated' problems resulting from 'switches'. This challenges the theory that drugs with a narrow therapeutic window (such as phenytoin) are more likely to cause problems after 'switches', than those without, like sodium valproate ~7. 'Validated' problems occurred when 'switching' between generic products, generic to brand and brand to generic, suggesting any 'switch' rather than a quality problem with a particular supply is the concern.
Approximately 360000 people are being treated for epilepsy 23. If all 'switched' supplies of their antiepileptic medication this study suggests that approximately 39 000 would suffer 'validated' problems and 106000 would perceive some problems. What are the health and economic costs?
Generic prescribing decreases drug costs 19, although presently, for AEDs the margin between generic and proprietary drugs is tiny, representing little opportunity for savings 24. However, generic prescribing for epilepsy may increase other costs.
Practices are likely to experience a rise in consultations and enquiries from people after a 'switch'. Accurate costs for this increased work are difficult to measure, but Jumao-as et al in the USA 4 found this additional cost averaged $140 (£93.00) per patient, per annum.
Problems resulting from a 'switch', especially increased seizure frequency or side-effects, could increase social costs through increased sick leave, loss of employment and other welfare benefits.
CONCLUSIONS
This study supports the argument against generic prescribing for epilepsy. It suggests that the small amount of money saved by generic prescribing is outweighed by negative health gain for the person with epilepsy, increased work in general practice, and increased social costs.
Epilepsy is unique in its potential adverse psycho-social implications. Generic prescribing may make such consequences more likely.
Unless the safety of generic prescribing for epilepsy can be more strongly substantiated should the Department of Health continue to advocate this policy?
